PortfoliosLab logoPortfoliosLab logo
Charles River Laboratories International, Inc. (CR...
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN
US1598641074
CUSIP
159864107
IPO Date
Jun 23, 2000

Highlights

Market Cap
$8.49B
Enterprise Value
$10.85B
EPS (TTM)
-$2.93
Total Revenue (TTM)
$4.02B
Gross Profit (TTM)
$1.01B
EBITDA (TTM)
$319.45M
Year Range
$91.86 - $228.88
Target Price
$214.43
ROA (TTM)
-2.02%
ROE (TTM)
-4.56%

Share Price Chart


Loading graphics...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Charles River Laboratories International, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


Loading graphics...

S&P 500 Index

Returns By Period

Charles River Laboratories International, Inc. (CRL) has returned -13.53% so far this year and 14.60% over the past 12 months. Over the last ten years, CRL has returned 8.32% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.


Charles River Laboratories International, Inc.

1D
8.00%
1M
-3.36%
YTD
-13.53%
6M
10.25%
1Y
14.60%
3Y*
-5.10%
5Y*
-10.13%
10Y*
8.32%

Benchmark (S&P 500 Index)

1D
2.91%
1M
-5.09%
YTD
-4.63%
6M
-2.39%
1Y
16.33%
3Y*
16.69%
5Y*
10.18%
10Y*
12.16%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Monthly Returns

Based on dividend-adjusted daily data since Jun 23, 2000, CRL's average daily return is +0.06%, while the average monthly return is +1.14%. At this rate, your investment would double in approximately 5.1 years.

Historically, 57% of months were positive and 43% were negative. The best month was Jul 2000 with a return of +36.1%, while the worst month was Nov 2008 at -36.4%. The longest winning streak lasted 14 consecutive months, and the longest losing streak was 6 months.

On a daily basis, CRL closed higher 52% of trading days. The best single day was May 7, 2025 with a return of +18.7%, while the worst single day was Apr 10, 2025 at -28.1%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20265.51%-15.20%-3.36%-13.53%
2025-10.75%0.33%-8.95%-21.19%14.34%11.87%11.80%-3.73%-4.19%15.09%-1.07%11.98%8.06%
2024-8.51%17.53%6.59%-15.48%-8.98%-0.89%18.16%-18.99%-0.39%-9.34%11.47%-7.26%-21.91%
202311.63%-9.83%-7.99%-5.80%1.71%8.72%-0.34%-1.30%-5.24%-14.09%17.06%19.95%8.49%
2022-12.48%-11.71%-2.47%-14.95%-3.08%-8.59%17.09%-18.08%-4.12%7.85%7.69%-4.67%-42.17%
20213.68%10.46%1.29%14.71%1.67%9.45%10.00%9.08%-7.03%8.73%-18.46%2.98%50.80%

Benchmark Metrics

Charles River Laboratories International, Inc. has an annualized alpha of 8.00%, beta of 0.87, and R² of 0.22 versus S&P 500 Index. Calculated based on daily prices since June 26, 2000.

  • This stock captured 121.40% of S&P 500 Index gains and 108.36% of its losses — amplifying both gains and losses, but participating more in upside than downside.
  • R² of 0.22 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
8.00%
Beta
0.87
0.22
Upside Capture
121.40%
Downside Capture
108.36%

Return for Risk

Risk / Return Rank

CRL ranks 49 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.


CRL Risk / Return Rank: 4949
Overall Rank
CRL Sharpe Ratio Rank: 5050
Sharpe Ratio Rank
CRL Sortino Ratio Rank: 4848
Sortino Ratio Rank
CRL Omega Ratio Rank: 5151
Omega Ratio Rank
CRL Calmar Ratio Rank: 4949
Calmar Ratio Rank
CRL Martin Ratio Rank: 4949
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for Charles River Laboratories International, Inc. (CRL) and compare them to a chosen benchmark (S&P 500 Index).


CRLBenchmarkDifference

Sharpe ratio

Return per unit of total volatility

0.26

0.90

-0.64

Sortino ratio

Return per unit of downside risk

0.73

1.39

-0.66

Omega ratio

Gain probability vs. loss probability

1.12

1.21

-0.10

Calmar ratio

Return relative to maximum drawdown

0.32

1.40

-1.08

Martin ratio

Return relative to average drawdown

0.74

6.61

-5.86

Explore CRL risk-adjusted metrics in detail

Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.

Dividends

Dividend History


Charles River Laboratories International, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading graphics...

Worst Drawdowns

The table below displays the maximum drawdowns of the Charles River Laboratories International, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Charles River Laboratories International, Inc. was 78.23%, occurring on Apr 11, 2025. The portfolio has not yet recovered.

The current Charles River Laboratories International, Inc. drawdown is 62.36%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-78.23%Sep 27, 2021890Apr 11, 2025
-69.81%Aug 20, 200866Nov 20, 20081545Jan 13, 20151611
-47.06%Oct 2, 2000111Mar 12, 200178Jul 2, 2001189
-44.54%Feb 20, 202020Mar 18, 202050May 29, 202070
-39.6%Oct 24, 2002118Apr 14, 2003209Feb 11, 2004327

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading graphics...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Charles River Laboratories International, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Charles River Laboratories International, Inc. is priced in the market compared to other companies in the Diagnostics & Research industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for CRL relative to other companies in the Diagnostics & Research industry. Currently, CRL has a P/S ratio of 2.1. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for CRL in comparison with other companies in the Diagnostics & Research industry. Currently, CRL has a P/B value of 2.7. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items